Download Free Sample Report

The global Recombinant Protein Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

This report aims to provide a comprehensive presentation of the global market for Recombinant Protein Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Protein Drugs. This report contains market size and forecasts of Recombinant Protein Drugs in global, including the following market information:

• Global Recombinant Protein Drugs Market Revenue, 2018-2023, 2024-2032, ($ millions)
• Global Recombinant Protein Drugs Market Sales, 2018-2023, 2024-2032, (K Doses)
• Global top five Recombinant Protein Drugs companies in 2022 (%)

The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Recombinant DNA Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Recombinant Protein Drugs include Novo Nordisk, Amgen, Sanofi, Eli Lilly, Merck Serono, Ortho Biotech, Roche, Kyowa Hakko Kirin and Pharmingen, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Recombinant Protein Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Recombinant Protein Drugs Market, by Type, 2018-2023, 2024-2032 ($ Millions) & (K Doses)
Global Recombinant Protein Drugs Market Segment Percentages, by Type, 2022 (%)

• Recombinant DNA
• Recombinant RNA

Global Recombinant Protein Drugs Market, by Application, 2018-2023, 2024-2032 ($ Millions) & (K Doses)
Global Recombinant Protein Drugs Market Segment Percentages, by Application, 2022 (%)

• Pharmaceutical Industry
• Others

Global Recombinant Protein Drugs Market, By Region and Country, 2018-2023, 2024-2032 ($ Millions) & (K Doses)
Global Recombinant Protein Drugs Market Segment Percentages, By Region and Country, 2022 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Recombinant Protein Drugs revenues in global market, 2018-2023 (Estimated), ($ millions)
• Key companies Recombinant Protein Drugs revenues share in global market, 2022 (%)
• Key companies Recombinant Protein Drugs sales in global market, 2018-2023 (Estimated), (K Doses)
• Key companies Recombinant Protein Drugs sales share in global market, 2022 (%)

Key players include:

• Novo Nordisk
• Amgen
• Sanofi
• Eli Lilly
• Merck Serono
• Ortho Biotech
• Roche
• Kyowa Hakko Kirin
• Pharmingen
• Abcam
• GenSci
• SL PHARM
• Dongbao Pharm
• Ankebio
• NCPC
• Heng Rui

Outline of Major Chapters:
Chapter 1: Introduces the definition of Recombinant Protein Drugs, market overview.
Chapter 2: Global Recombinant Protein Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Recombinant Protein Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Recombinant Protein Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Recombinant Protein Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.